Long-term follow up and related risk factors analysis in patients with boost radiotherapy in the management of liver metastases
10.3760/cma.j.issn.1007-631X.2018.08.016
- VernacularTitle:肝转移癌患者3D后程放疗长期随访及相关危险因素研究
- Author:
Kai LU
1
;
Xuefeng YANG
;
Hongmei SUN
;
Qingshan YOU
Author Information
1. 大庆油田总医院普外四科
- Keywords:
Liver neoplasms;
Neoplasm metastasis;
Chemoradiotherapy;
Survival rate
- From:
Chinese Journal of General Surgery
2018;33(8):678-681
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect and prognostic factors of patients with liver metastases treated with three dimensional conformal radiation therapy (3-DCRT) with boost radiotherapy.Methods From Jan 2010 to Jan 2016,120 patients of liver metastases treated in the Third Rradiotherapy Department of the Third Affiliated Hospital of Harbin Medical University (all patients were treated for the first time and were not suitable for surgical treatment) were restrospectively analyzed.Results 1,2,3-year survival rates were 74.7％,20.2,13.5％,median survival was 19 months.For univariate analysis,those with less number of extrahepatic organ metastasis,fewer liver metastases,smaller size of liver metastases,higher radiation dose,no chemotherapy before radiation and Karnofsky score ≥80 points were with higher 1-,2-and 3-year survival rate and longer median survival time (P ＜ 0.05).Multivariate analysis showed that the number of involved extrahepatic organs,the maximum diameter of liver metastases,numbers of metastases and radiation dose are independent factors to affect the survival of patients with liver metastases (P ＜ 0.05).Conclusions Patients with liver metastases treated with 3D-CRT and boost radiotherapy have satisfactory local control and 1,2,3-year survival rate as well as lower incidence of toxicity damage to the liver.
